KRYSKrystal Biotech, Inc.Signing up patients
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Lung Cancer, Non-small Cell · Lung Cancer Metastatic · Solid Tumor, Adult · Advanced Cancer · Lung Cancer (NSCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 250 (planned)
- Started
- Apr 17, 2024
- Main results expected
- Feb 2027
- Fully finished
- Jul 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)
Measured over: up to 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06228326 · record last updated 2025-10-24 · checked 2026-11-09 15:47 UTC